Active, not recruitingPhase 3NCT05345171
Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency
Studying Ornithine transcarbamylase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ultragenyx Pharmaceutical Inc
- Principal Investigator
- Medical DirectorUltragenyx Pharmaceutical Inc
- Intervention
- DTX301(genetic)
- Enrollment
- 32 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2022 – 2031
Study locations (16)
- University of California, Los Angeles, California, United States
- University of Colorado, Aurora, Colorado, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
- Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
- Clinica Universitaria Reina Fabiola, Córdoba, Argentina
- Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
- The Hospital for Sick Children, Toronto, Ontario, Canada
- Hopital Femme Mere Enfant, Bron, France
- Necker-Enfants Maladas Hospital, Paris, France
- Universitatsklinikum Heidelberg, Heidelberg, Germany
- Kumamoto University Hospital, Kumamoto, Japan
- Fujita Health University Hospital, Toyoake, Japan
- Erasmus Universitair Medisch Centrum Rotterrdam, Rotterdam, Netherlands
- Centro Hospitalar Universitario de Sao Joao, Porto, Portugal
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05345171 on ClinicalTrials.govOther trials for Ornithine transcarbamylase deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06805695Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)iECURE, Inc.
- RECRUITINGPHASE2NCT06488313A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCDArcturus Therapeutics, Inc.
- RECRUITINGPHASE1, PHASE2NCT06255782An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC DeficiencyiECURE, Inc.
- RECRUITINGPHASE1, PHASE2NCT05092685Halting Ornithine Transcarbamylase Deficiency With Recombinant AAV in ChildrEnUniversity College, London
- RECRUITINGNCT04908319Hepatic Histopathology in Urea Cycle DisordersBaylor College of Medicine
- ACTIVE NOT RECRUITINGNCT04612764Liver Disease in Urea Cycle DisordersBaylor College of Medicine
- ACTIVE NOT RECRUITINGNCT03636438Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC DeficiencyUltragenyx Pharmaceutical Inc